台股 » 個股 » 訊聯 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

訊聯

(1784)
可現股當沖
  • 股價
    83.1
  • 漲跌
    ▲2.3
  • 漲幅
    +2.85%
  • 成交量
    221
  • 產業
    上櫃 生技醫療類股
  • 119人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
訊聯 (1784)籌碼相關-元大-南京 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

元大-南京 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/2000.001.180.7181.30-1.1440-0.24%
2025/01/1600.00181.6082.20-1455-0.22%
2025/01/1500.000.282.8081.90-0.2460-0.04%
2025/01/14184.20184.1084.1004600.00%
2025/01/0600.00181.8081.50-1475-0.21%
2024/12/31279.5000.0079.5024810.42%
2024/12/26181.80281.7080.90-1525-0.19%
2024/12/2500.00280.1080.30-2521-0.38%
2024/12/19080.7000.0079.5005470.00%
2024/12/13090.0700.0087.2005870.01%
2024/12/122.292.8300.0092.602.25800.38%
2024/12/0400.000.2102.00100.50-0.2550-0.03%
2024/11/29296.403.196.9297.00-1.1519-0.22%
2024/11/25397.90397.4097.4005650.00%
2024/11/201.294.47393.8795.90-1.8565-0.32%
2024/11/120.490.4000.0089.100.46530.06%
2024/11/040.390.5100.0090.800.37910.04%
2024/11/010.391.2000.0091.200.38240.03%
2024/10/290.392.5000.0092.500.38640.03%
2024/10/2800.00094.8093.5008790.00%
2024/10/180.794.0100.0093.100.71,4300.05%
2024/10/0100.002100.50102.00-21,687-0.12%
2024/09/302103.251.1102.47100.000.91,7060.05%
2024/09/24197.0000.0096.6012,2460.04%
2024/09/194103.8800.00102.5042,2880.17%
2024/09/1800.001116.50116.50-12,273-0.04%
2024/08/301118.5000.00116.5012,7630.04%
2024/08/291119.501118.00118.0002,8210.00%
2024/08/2800.002120.25119.00-22,888-0.07%
2024/08/263119.0000.00120.5032,9860.10%
2024/08/231114.501115.50115.0003,0100.00%
2024/08/2200.004116.75114.50-43,003-0.13%
2024/08/2100.001116.50117.00-12,998-0.03%
2024/08/202119.753118.67116.00-12,973-0.03%
2024/08/151114.0000.00113.0012,9360.03%
2024/08/132108.252109.00113.5002,9810.00%
2024/08/121114.001115.00112.0002,9620.00%
2024/08/0700.001.1108.47108.50-1.12,906-0.04%
2024/08/06199.501103.50103.0002,8900.00%
2024/08/0500.00399.5099.50-32,853-0.11%
2024/08/024113.251115.50110.5032,8180.11%
2024/08/011118.505118.60117.00-42,802-0.14%
2024/07/302118.252115.50116.5002,7790.00%
2024/07/292116.743.2119.13113.50-1.22,748-0.04%
2024/07/261124.003125.83126.00-22,692-0.07%
2024/07/231131.003131.53132.00-22,666-0.08%
2024/07/229.1138.253136.00136.006.12,6470.23%
2024/07/1917154.273157.17145.50142,5720.55%
2024/07/181156.5018153.53161.50-172,302-0.74%
2024/07/164142.6300.00141.5042,1980.18%
2024/07/151142.001145.00143.5002,1960.00%
2024/07/1211144.5000.00139.00112,1770.51%
2024/07/117143.071140.00140.0062,1630.28%
2024/07/1000.000148.00147.5002,1440.00%
2024/07/092142.755.2144.00143.50-3.22,130-0.15%
2024/07/081140.006.3140.08146.00-5.32,083-0.25%
2024/07/053136.172.2134.14133.000.92,0390.04%
2024/07/049.1130.940.1131.00135.5092,0270.44%
2024/07/030.1137.001133.50133.00-0.92,008-0.04%
2024/07/029.3138.582.1137.94140.007.21,9350.37%
2024/07/016.3130.757134.79139.50-0.71,729-0.04%
2024/06/284122.906124.00127.00-21,623-0.12%
2024/06/2700.002115.50115.50-21,436-0.14%
2024/06/2600.004105.00105.00-41,428-0.28%
2024/06/21197.10594.3293.70-41,351-0.30%
2024/06/20197.5000.0099.4011,3080.08%
2024/06/18297.35196.3096.1011,2420.08%
2024/06/14585.00585.5287.7001,1530.00%
2024/06/13186.50187.9085.3001,1250.00%
2024/06/11183.90284.8082.80-11,051-0.10%
2024/06/07182.601085.5883.00-91,017-0.88%
2024/06/06483.73483.0381.2009690.00%
2024/06/05183.701583.5687.00-14907-1.54%
2024/06/04781.43482.8580.0038360.36%
2024/06/03484.1300.0085.0047730.52%
2024/05/31380.3700.0082.4036900.43%
2024/05/30175.00178.0077.3006070.00%
2024/05/29173.601873.4274.00-17547-3.11%
2024/05/24167.1000.0067.2014930.20%
2024/05/22369.90171.0069.6024870.41%
2024/05/21171.6000.0070.0014790.21%
2024/05/20170.00772.0771.70-6471-1.27%
2024/05/1700.00670.4369.90-6454-1.32%
2024/05/1500.00567.2066.70-5419-1.19%
2024/05/022767.27766.8166.50203805.25%
2024/04/2300.00262.8564.10-2288-0.69%
2024/04/2200.00560.8060.80-5278-1.80%
2024/04/19859.0400.0058.8082812.84%
2024/04/17065.0000.0061.8002800.00%
2024/03/2000.00266.3066.00-2251-0.80%
2024/03/04062.5000.0062.5002240.00%
訊聯2024年外泌體與幹細胞趨勢論壇 聚焦羊水與臍帶血應用Anue鉅亨-2024/12/25
訊聯H1外泌體業績年增1.8倍 旗下訊聯細胞智藥擬Q4登興櫃Anue鉅亨-2024/08/26
訊聯 相關文章
訊聯 相關影音